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OBJECTIVES The purpose of this study was to compare the effect of different antihypertensive agents,
calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers and
diuretic agents on endothelial function.
BACKGROUND Endothelial dysfunction is a component of essential hypertension, and various antihyperten-
sive drugs may be able to restore normal function.
METHODS Forearm blood flow (FBF) was measured in 296 patients with essential hypertension,
including 46 untreated subjects using strain-gauge plethysmography during reactive hyper-
emia and after sublingual administration of nitroglycerin (NTG). Forty-seven normotensive
subjects were similarly evaluated as control subjects.
RESULTS The FBF during reactive hyperemia in the 296 hypertensive patients was significantly less
than that in age-matched normotensive subjects. The increase in FBF after administration of
sublingual NTG was similar in both groups. Systolic and diastolic blood pressures and
forearm vascular resistance were greater in the untreated group than in the four treated groups
and did not differ with respect to the antihypertensive agent used. The maximal FBF response
from reactive hyperemia was significantly greater in the ACE inhibitor–treated group than in
the group treated with calcium antagonists, beta-blockers, diuretic agents, or nothing (40.5 6
5.2 vs. 32.9 6 5.8, 34.0 6 5.6, 32.1 6 5.9, and 31.9 6 5.8 ml/min per 100 ml tissue, p ,
0.05, respectively). Reactive hyperemia was similar in the calcium antagonist, beta-blocker,
diuretic and untreated groups, and changes in FBF after sublingual NTG administration were
similar in all groups. The infusion of NG-monomethyl-L-arginine, a nitric oxide (NO)
synthase inhibitor, abolished the enhancement of reactive hyperemia in hypertensive patients
treated with ACE inhibitors.
CONCLUSIONS These findings suggest that ACE inhibitors augment reactive hyperemia, an index of
endothelium-dependent vasorelaxation, in patients with essential hypertension. This aug-
mentation may be due to increases in NO. (J Am Coll Cardiol 2000;35:284–91) © 2000 by
the American College of Cardiology
Essential hypertension is associated with alterations in
endothelial function. Endothelium-dependent vasodilation
in response to substances such as acetylcholine, bradykinin
and substance P and reactive hyperemia was reduced in
brachial (1–3), coronary (4) and renal arteries (5,6) in
patients with essential hypertension. Impairment of endo-
thelial function has been shown to play an important role in
the development and maintenance of hypertension (7).
Several studies have demonstrated the restoration of
endothelial function in essential hypertensive patients
through the administration of antihypertensive agents (8,9),
especially angiotensin-converting enzyme (ACE) inhibitors.
Recently, we also have reported that a 12-week treatment
with ACE inhibitor, but not calcium channel antagonist,
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improves endothelium-dependent renovascular relaxation in
patients with essential hypertension (10). In contrast, Crea-
ger et al. (11) have shown that effective antihypertensive
therapy, including ACE inhibitors, did not restore impaired
endothelium-dependent vasodilation in the forearm circu-
lation of hypertensive patients. Although the results of
experimental studies have supported the beneficial effect of
ACE inhibitors on endothelial function (12,13), data on the
forearm circulation of humans are controversial. In addition,
the effect of other classes of antihypertensive agents on
endothelial function has not been fully evaluated in human
hypertension. It may be clinically important to select an
appropriate antihypertensive agent that is effective in im-
proving endothelial dysfunction in patients with established
essential hypertension.
Thus, we compared the effects of the most frequently
prescribed classes of antihypertensive agents on endothelial
function in patients with essential hypertension. We mea-
sured the response of forearm blood flow (FBF) to reactive
hyperemia, an index of endothelium-dependent vasodila-
tion, and to the sublingual administration of nitroglycerin
(NTG), an index of endothelium-independent vasodilation.
METHODS
Subjects. The study group consisted of 296 Japanese pa-
tients with essential hypertension (162 men and 134 wom-
en; mean age 52 6 9 years) and 47 normotensive subjects
(27 men and 20 women; mean age 48 6 12 years).
Hypertension was defined as a systolic blood pressure
.160 mm Hg and/or a diastolic blood pressure
.95 mm Hg, determined in a sitting position on at least
three different occasions. Patients receiving any antihyper-
tensive medications were considered to be hypertensive.
Patients with secondary forms of hypertension, as suggested
by clinical and biochemical examinations, were excluded
from the study. Patients with a history of cardiovascular or
cerebrovascular disease, diabetes mellitus or hepatic or renal
disease were excluded. Patients receiving monotherapy with
either calcium antagonists, ACE inhibitors, beta-blockers
or diuretic agents were randomly recruited. All patients
receiving antihypertensive drugs were treated for .24
weeks. Normotension was defined as a systolic blood pressure
,140 mm Hg and a diastolic blood pressure ,80 mm Hg.
The normotensive control subjects had no history of serious
disease and took no medication for at least four weeks before
the study. The study protocol was approved by the Ethics
Committee of the First Department of Internal Medicine of
Hiroshima University. Informed consent for participation
was obtained from all subjects.
Measurement of FBF. The FBF was measured using a
mercury-filled Silastic strain-gauge plethysmograph (EC-
5R, D.E. Hokanson, Inc., Issaquah, Washington) as previ-
ously described (1,2). The strain-gauge was attached to the
left upper arm supported above the right atrium and
connected to a plethysmography device. A wrist cuff was
inflated to a pressure of 50 mm Hg above the systolic blood
pressure to exclude the hand circulation from the measure-
ments 1 min before each measurement and throughout
measurement of FBF. The upper arm–congesting cuff was
inflated to 40 mm Hg for 7 s in each 15-s cycle to occlude
venous outflow from the arm by using a rapid cuff inflator
(EC-20, D.E. Hokanson, Inc.). The FBF output signal was
transmitted to a recorder (U-228, Advance Co., Nagoya,
Japan). The FBF was expressed as milliliters per minute per
100 ml of tissue of forearm volume. Then FBF was
calculated by two independent observers who had no knowl-
edge of the subjects’ profile, including the drug(s) used and
results from the linear portions of the plethysmographic
recordings. The intraobserver coefficient of variation was
3 6 1.7%.
Study protocol. The study began at 8:30 AM after the
subjects fasted for at least 12 h. The subjects were kept in
the supine position in a quiet, dark, air-conditioned room
(constant temperature 22°C to 25°C) throughout the study.
After 30 min in the supine position, basal FBF was
measured. Then, the effect of reactive hyperemia and
sublingual NTG on FBF was measured. To induce reactive
hyperemia, FBF was occluded by inflating the cuff on the
left upper arm to a pressure of 280 mm Hg for 5 min. After
release of the ischemic cuff occlusion, FBF was measured for
3 min. Nitroglycerin, 0.3 mg (Nihonkayaku Co., Tokyo,
Japan) was then administered sublingually, and FBF was
measured for 5 min. These studies were carried out in a
randomized fashion, and each study proceeded after FBF
had returned to baseline. In the preliminary study, after the
release of cuff occlusion or the sublingual NTG, FBF
returned to baseline within 10 min. Thus, the end of the
response to reactive hyperemia or sublingual NTG was
followed by a 15-min recovery period. Baseline fasting
serum concentrations of total cholesterol, high density
lipoprotein (HDL) cholesterol, triglycerides, creatinine, in-
sulin, glucose and electrolytes, as well as plasma renin
activity, were obtained after a 30-min rest period.
To evaluate the effects of the antihypertensive drugs on
nitric oxide (NO) and prostaglandin release, we measured
the FBF response to reactive hyperemia in the presence of a
NO synthase inhibitor, NG-monomethyl-L-arginine (L-
NMMA) (Sigma Chemical Co., St. Louis, Missouri), and a
prostaglandin synthesis inhibitor, indomethacin (Banyu
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
FBF 5 forearm blood flow
HDL 5 high density lipoprotein
L-NMMA 5 NG-monomethyl-L-arginine
NO 5 nitric oxide
NTG 5 nitroglycerin
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Pharmaceutical Co., Tokyo, Japan), in 13 hypertensive
patients treated with ACE inhibitors (9 men and 4 women;
mean age 52 6 12 years), 15 hypertensive patients treated
with other agents (calcium antagonists [n 5 9], beta-
blockers [n 5 3] and diuretic agents [n 5 3]; 8 men and 7
women; mean age 54 6 13 years) and 18 untreated
hypertensive patients (12 men and 6 women; mean age
50 6 14 years). Responses of the forearm vasculature to
reactive hyperemia after an intra-arterial infusion of
L-NMMA or oral administration of indometacin were
evaluated on separate occasions. A 23-gauge polyethylene
catheter (Hakkow Co., Okayama, Japan) was inserted under
local anesthesia (1% lidocaine) into the left brachial artery
for infusion of L-NMMA. After maintaining the supine
position for 30 min, we measured basal FBF. Then the
effect of reactive hyperemia on forearm hemodynamic data
was measured. After a 15-min recovery period, L-NMMA
was infused intra-arterially at a dose of 8 mmol/min for
5 min before FBF measurement. We performed reactive
hyperemia after initiation of a 5-min infusion of L-NMMA
or 1 h after oral administration of indomethacin (50 mg).
In the preliminary study, we confirmed the reproducibil-
ity of reactive hyperemia and sublingual NTG-induced
vasodilation on two separate occasions in 28 healthy male
subjects (mean age 27 6 5 years). The coefficients of
variation were 4.3% and 2.8%, respectively.
Analytical methods. Venous blood samples were obtained
in tubes containing EDTA-sodium (1 mg/ml) and in
polystyrene tubes. The EDTA-containing tubes were
promptly chilled in an ice bath. Plasma was immediately
separated by centrifugation at 3,100 rpm at 4°C for 10 min,
and serum at 1,000 rpm at room temperature for 10 min.
Samples were stored at 280°C until assayed. Routine
chemical methods were used to determine serum concen-
trations of total cholesterol, HDL cholesterol, triglycerides,
creatinine, glucose and electrolytes. The serum concentra-
tion of low density lipoprotein was estimated using Friede-
wald’s method (14).
Statistical analysis. Results are presented as the mean
value 6 SD. Values of p , 0.05 were considered significant.
The Mann-Whitney U test was used to evaluate differences
between the hypertensive patients and normotensive sub-
jects. Comparisons of time course curves of FBF during
reactive hyperemia were analyzed by two-way analysis of
variance (ANOVA) for repeated measures on one factor
followed by the Bonferroni correction for multiple-paired
comparisons. The repeated factor was time of reactive
hyperemia and the nonrepeated factor was one group versus
the other group (Fig. 1). Multigroup comparisons of vari-
ables, including maximal FBF response to NTG (Fig. 2),
was carried out by one-way ANOVA followed by the
Bonferroni correction. Two-way ANOVA for repeated
measures on two factors was used to analyze the effect of
L-NMMA or indomethacin on time course curves of FBF
during reactive hyperemia. One factor was time of reactive
hyperemia, and the other was before versus after L-NMMA
or indomethacin administration (Fig. 3). If an interactive
effect of drug reached statistical significance, the nature of
this interaction was further investigated by applying two-
Figure 1. Forearm blood flow at rest and during reactive hyper-
emia in the normotensive control subjects (n 5 47), hypertensive
patients treated with calcium antagonists (n 5 175), ACE inhib-
itors (n 5 51), beta-blockers (n 5 14) and diuretic agents (n 5 10)
and untreated hypertensive patients (n 5 46). Reactive hyperemia
was impaired in hypertensive patients as compared with normo-
tensive subjects (p , 0.01). Reactive hyperemia was greater in
hypertensive patients treated with ACE inhibitors than in those
treated with calcium antagonists (p , 0.01), beta-blockers (p ,
0.01) and diuretic agents (p , 0.05) and untreated hypertensive
patients (p , 0.01). Reactive hyperemia was similar among
calcium antagonist, beta-blocker, diuretic agent and untreated
groups.
Figure 2. Maximal forearm blood flow after the sublingual admin-
istration of NTG in normotensive control subjects (n 5 47),
hypertensive patients treated with calcium antagonists (n 5 175),
ACE inhibitors (n 5 51), beta-blockers (n 5 14) and diuretic
agents (n 5 10) and untreated hypertensive patients (n 5 46).
Nitroglycerin-induced vasodilation was similar in all six groups.
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way ANOVA for repeated measured to all six groups
(normotensive subjects, untreated hypertensive subjects,
those treated with calcium antagonists, ACE inhibitors,
beta-blockers and diuretic agents) without consideration of
the factorial design. The data were processed using Stat-
View IV (Brainpower) and Super ANOVA (Abacus Con-
cepts) software packages.
RESULTS
Clinical characteristics. The baseline clinical characteris-
tics of the 296 hypertensive patients, including 46 untreated
individuals, and the 47 normotensive subjects appear in
Table 1. The antihypertensive drugs used in patients with
established essential hypertension are listed in Table 2. The
systolic and diastolic blood pressures and forearm vascular
resistance were significantly higher in the hypertensive
patients than in the normotensive subjects. These variables
were higher in the untreated hypertensive patients than in
the treated hypertensive patients. All other variables were
similar in the hypertensive patients and the normotensive
subjects (Table 1).
Effect of calcium antagonists, ACE inhibitors, beta-
blockers and diuretic agents on endothelial function.
The time course curve of FBF during reactive hyperemia, an
index of endothelium-dependent vasorelaxation, was signif-
icantly less in essential hypertensive patients than in nor-
motensive subjects (p , 0.01), regardless of whether they
received antihypertensive treatment; the ACE inhibitor
(p , 0.01), calcium antagonist (p , 0.01), beta-blocker
(p , 0.01), diuretic agent (p , 0.01) and untreated
hypertensive groups (p , 0.001) were compared with the
normotensive group (Fig. 1). Reactive hyperemia was sig-
nificantly greater in the ACE inhibitor–treated group than
in the calcium antagonist (p , 0.01), beta-blocker (p ,
0.01), diuretic agent (p , 0.05) or untreated groups (p ,
0.01) but was similar among the last four groups (Fig. 1).
Maximal FBF was 46.5 6 6.2 ml/min per 100 ml tissue in
normotensive subjects and 34.1 6 5.9 ml/min per 100 ml
tissue in hypertensive patients (p , 0.05). In the hyperten-
sive subgroups, maximal FBF was 40.5 6 5.2 ml/min per
100 ml tissue in those treated with ACE inhibitors, 32.9 6
5.8 ml/min per 100 ml tissue in those treated with calcium
antagonists, 34.0 6 5.6 ml/min per 100 ml tissue in those
treated with beta-blockers, 32.1 6 5.9 ml/min per 100 ml
tissue in those treated with diuretic agents and 31.9 6
5.8 ml/min per 100 ml tissue in untreated hypertensive
subjects (p , 0.05 vs. normotensive subjects). Maximal FBF
was significantly greater in the ACE inhibitor group than in
the calcium antagonist, beta-blocker or diuretic agent group
or in the untreated hypertensive subjects (p , 0.05) but was
similar among the last four groups. In the ACE inhibitor
group, there was no significant difference in reactive hyper-
emia between imidapril (maximal FBF: 42.1 6 7.1 ml/min
per 100 ml tissue) and enalapril maleate (maximal FBF:
40.2 6 6.6 ml/min per 100 ml tissue). In the calcium
antagonist group, there was no significant difference in
reactive hyperemia between amlodipine (maximal FBF:
31.4 6 6.7 ml/min per 100 ml tissue), slow-release nifedipine
(maximal FBF: 33.5 6 6.4 ml/min per 100 ml tissue),
nilvadipine (maximal FBF: 32.7 6 6.8 ml/min per 100 ml
tissue) and nicardipine hydrochloride (maximal FBF: 33.0 6
6.7 ml/min per 100 ml tissue).
The increase in FBF after sublingual administration of
NTG, an index of endothelium-independent vasodilation,
was similar among all six groups (normotensive subjects:
5.6 6 1.3; untreated hypertensive subjects: 5.4 6 1.4;
calcium antagonist group: 5.7 6 1.4; ACE inhibitor group:
Figure 3. Forearm blood flow at rest and during reactive hyper-
emia after the administration of L-NMMA, an NO synthase
inhibitor, or indomethacin, a prostaglandin synthesis inhibitor, in
hypertensive patients treated with ACE inhibitors (n 5 13) or
other agents (n 5 15) and in untreated hypertensive patients (n 5
18). L-NMMA abolished the enhancement of reactive hyperemia
in hypertensive patients treated with ACE inhibitors (top). Indo-
methacin did not affect reactive hyperemia in any group (bottom).
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5.3 6 1.4; beta-blocker group: 5.4 6 1.5; and diuretic agent
group: 5.5 6 1.3 ml/min per 100 ml tissue, p 5 NS) (Fig.
2).
Effect of L-NMMA and indomethacin on reactive hy-
peremia. Intra-arterial infusion of L-NMMA reduced
basal FBF (ACE inhibitor group: 4.6 6 1.3 to 2.4 6
Table 1. Clinical Characteristics of the Normotensive Subjects, Patients With Essential Hypertension Treated With Calcium
Antagonists, Angiotensin-Converting Enzyme Inhibitors, Beta-Blockers and Diuretic Agents and the Untreated Group
Variable
Normotensive
Subjects
(n 5 47)
Untreated
Hypertensive
Subjects
(n 5 46)
Hypertensive Patients
Calcium
Antagonists
(n 5 175)
ACE
Inhibitors
(n 5 51)
Beta-Blockers
(n 5 14)
Diuretic
Agents
(n 5 10)
Age (years) 48 6 12 51 6 13 54 6 11 53 6 10 57 6 9 59 6 10
Gender (F/M) 20/27 20/26 79/96 25/26 6/8 4/6
Body mass index (kg/m2) 23.6 6 2.7 24.2 6 2.8 23.9 6 2.7 23.7 6 3.1 23.5 6 2.7 24.1 6 1.9
Systolic blood pressure (mm Hg) 116.1 6 10.3 158.2 6 13.2* 140.3 6 14.1*† 143.1 6 13.8*† 146.3 6 13.5*† 145.2 6 12.8*†
Diastolic blood pressure (mm Hg) 69.0 6 8.6 96.8 6 10.1* 82.4 6 10.6*† 84.5 6 10.4*† 85.7 6 9.9*† 86.3 6 10.7*†
Heart rate (beats/min) 68.6 6 7.9 70.3 6 8.8 71.2 6 9.0 69.6 6 8.9 64.0 6 9.2 72.2 6 10.1
Total cholesterol (mmol/liter) 4.81 6 0.69 5.01 6 0.74 4.97 6 0.60 4.78 6 0.62 5.04 6 0.71 5.11 6 0.76
Triglycerides (mmol/liter) 1.11 6 0.38 1.17 6 0.33 1.14 6 0.40 1.08 6 0.42 1.15 6 0.39 1.20 6 0.48
HDL cholesterol (mmol/liter) 1.45 6 0.31 1.42 6 0.25 1.46 6 0.33 1.39 6 0.32 1.42 6 0.35 1.49 6 0.42
LDL cholesterol (mmol/liter) 3.14 6 0.56 3.36 6 0.69 3.29 6 0.57 3.17 6 0.59 3.39 6 0.62 3.38 6 0.68
Serum glucose (mmol/liter) 4.7 6 0.4 4.9 6 0.3 5.0 6 0.3 4.8 6 0.3 4.9 6 0.2 5.0 6 0.3
FBF (ml/min per 100 ml tissue) 4.6 6 1.2 4.5 6 1.3 4.4 6 1.4 4.5 6 1.3 4.5 6 1.2 4.5 6 1.3
FVR (mm Hg/ml per min
per 100 ml tissue)
18.4 6 4.1 25.7 6 3.2* 23.1 6 4.3*† 23.0 6 4.2*† 23.4 6 4.5*† 23.5 6 4.6*†
Smoker (%) 28 30 26 32 33 20
*p , 0.05 versus normotensive group. †p , 0.05 versus untreated hypertensive group. Data are presented as the mean value 6 SD.
ACE 5 angiotensin-converting enzyme; F 5 female; FBF 5 forearm blood flow; FVR 5 forearm vascular resistance; HDL 5 high density lipoprotein; LDL 5 low density
lipoprotein; M 5 male.
Table 2. Antihypertensive Drugs Used in Patients With Essential Hypertension
Class of Drug Name of Drug Males Age (yrs)*
Calcium antagonists
Amlodipine (n 5 67) 35 52 6 9
Nifedipine, slow release (n 5 58) 36 55 6 10
Nilvadipine (n 5 18) 9 56 6 12
Nicardipine (n 5 14) 8 55 6 11
Nitrendipine (n 5 8) 4 52 6 13
Benidipine (n 5 6) 2 57 6 14
Aranidipine (n 5 4) 2 52 6 10
ACE inhibitors
Imidapril (n 5 24) 12 54 6 14
Enalapril (n 5 16) 9 51 6 13
Temocapril (n 5 5) 2 54 6 11
Perindopril (n 5 4) 2 55 6 10
Alacepril (n 5 2) 1 62 6 7
Beta-blockers
Carteolol (n 5 5) 3 60 6 9
Bunitrolol (n 5 4) 2 59 6 10
Metoprolol (n 5 3) 2 58 6 8
Bisoprolol (n 5 2) 1 55 6 7
Diuretic agents
Imdapamide (n 5 4) 1 63 6 9
Trichlomethiazide (n 5 4) 2 59 6 10
Spironolactone (n 5 2) 1 56 6 9
*Data are presented as the mean value 6 SD.
ACE 5 angiotensin-converting enzyme.
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0.4 ml/min per 100 ml tissue; other agent group: 4.5 6 1.3
to 2.5 6 0.5 ml/min per 100 ml tissue; untreated group:
4.4 6 1.3 to 2.4 6 0.4 ml/min per 100 ml tissue, p , 0.05)
and abolished the augmentation in FBF response to reactive
hyperemia in patients treated with ACE inhibitors (p ,
0.001) (maximal FBF: 41.8 6 7.5 to 31.5 6 7.3 ml/min per
100 ml tissue, p , 0.05). Infusion of L-NMMA reduced
reactive hyperemia in the other agent groups and untreated
hypertensive groups (p , 0.001) (maximal FBF: 34.2 6 7.1
to 27.6 6 6.7 ml/min per 100 ml tissue in the other agent
groups; 32.2 6 6.6 to 26.0 6 6.9 ml/min per 100 ml tissue
in the untreated hypertensive groups, p , 0.05). After
L-NMMA infusion, reactive hyperemia was similar among
the three groups (p 5 NS) (Fig. 3, top). L-NMMA
infusion did not alter arterial blood pressure or heart rate in
any group.
Oral administration of indomethacin did not significantly
change arterial blood pressure, heart rate, basal FBF or
reactive hyperemia in any group (Fig. 3, bottom). After
indomethacin administration, maximal FBF ranged from
40.6 6 7.1 to 41.1 6 7.3 ml/min per 100 ml tissue in the
ACE inhibitor group; 34.0 6 6.9 to 33.5 6 6.7 ml/min per
100 ml tissue in other agent groups; and 31.8 6 6.8 to
31.0 6 6.6 ml/min per 100 ml tissue in the untreated
hypertensive group (p 5 NS).
DISCUSSION
The present study demonstrates that reactive hyperemia, an
index of endothelium-dependent vasodilation, is impaired
in essential hypertensive patients as compared with normo-
tensive control subjects. In addition, reactive hyperemia in
patients treated with ACE inhibitors is significantly greater
than that in patients receiving calcium antagonists, beta-
blockers and diuretic agents. Furthermore, NO plays an
important role in the augmentation of reactive hyperemia in
hypertensive patients receiving ACE inhibitors. Although
all of these agents were effective in reducing blood pressure,
only ACE inhibitors improved endothelial dysfunction.
The forearm vascular response to reactive hyperemia was
impaired in patients with essential hypertension, although
NTG-induced vasodilation was similar in the hypertensive
and normotensive subjects, indicating that in hypertensive
patients, endothelial cells, but not smooth muscle cells, are
selectively impaired and may be restored. These findings are
consistent with previous studies that have demonstrated that
endothelium-dependent vasodilation of brachial (1–3), renal
(5,6), femoral (15) and small arteries is impaired in essential
hypertensive patients as compared with normotensive sub-
jects. Because reactive hyperemia increased in the ACE
inhibitor group only, and no significant difference in reactive
hyperemia existed between the different ACE inhibitors
or calcium antagonists, the effect of antihypertensive
therapy on endothelial function must not be specific for
one single medication. Reactive hyperemia in hyperten-
sive patients treated with ACE inhibitors was less than
that in normotensive subjects, suggesting that antihyper-
tensive therapy with ACE inhibitors may not completely
restore endothelial function to the level of that in
normotensive subjects.
Several experimental (12,13) and clinical studies (8–
10,16,17) support our results demonstrating that ACE
inhibitors can restore endothelial function, whereas other
studies report that antihypertensive therapy does not alter
endothelial function in hypertension (11,18). In the present
study, an NO synthase inhibitor, L-NMMA, abolished the
augmentation of reactive hyperemia in patients treated with
ACE inhibitors, suggesting that NO plays a major role in
this process. It is well known that a balance between
angiotensin II and NO is important in the regulation of
vascular tone (19). Angiotensin II increases vascular super-
oxide production through activation of membrane-
associated NADH/NADPH oxidase, resulting in NO in-
activation and toxic peroxynitrite production (19).
Therefore, ACE inhibitors may increase NO by inhibiting
angiotensin II production. Furthermore, under physiologic
conditions, endogenous bradykinin is limited by the ACE.
Bradykinin binds to B2 receptors on the endothelial cell
surface to release NO (20). The ACE inhibitors prevent
bradykinin degradation, leading to increases in NO release.
In addition, the decreased bradykinin degradation in-
duced by ACE inhibition has been shown to increase
prostaglandins (21). Because the prostaglandin synthesis
inhibitor indomethacin did not affect reactive hyperemia,
prostaglandins do not contribute to the augmentation of
reactive hyperemia by ACE inhibitors. These findings are
consistent with a previous study using aspirin, a cyclooxy-
genase inhibitor (22).
Although various types of antihypertensive drugs in the
present study were equally effective in reducing blood
pressure, the forearm vascular response to reactive hyper-
emia was greater in the ACE inhibitor group than in the
other three groups. In addition, although calcium antago-
nists, beta-blockers and diuretic agents all reduced blood
pressure significantly, the reactive hyperemia in these groups
was similar to that in the untreated hypertensive group. Our
findings are consistent with the results of previous studies
showing that blood pressure reduction with calcium antag-
onists and beta-blockers does not directly alter
endothelium-dependent vasodilation in brachial, renal and
small arteries in essential hypertensive patients (8–10).
Thus, the reduction in blood pressure with effective antihy-
pertensive therapy may not always lead to improved endo-
thelial function in patients with essential hypertension.
Study limitations. The use of agonists to stimulate NO
release, such as acetylcholine or methacholine, would allow
us to draw more specific conclusions regarding the role of
basal and stimulated release of NO by antihypertensive
agents in the forearm circulation. Recently, Celermajer et al.
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(23) demonstrated that a noninvasive method of reactive
hyperemia is useful in assessing endothelial function, instead
of the method that uses infusion of intra-arterial vasoactive
agents. Indeed, in the present study this technique was
simple and reproducible and did not lead to adverse effects.
We recommend that this noninvasive technique be used to
assess endothelial function both in future studies and in
routine clinical examinations.
Several limitations should be considered in assessing this
report. First, this is not a double-blind, placebo-controlled
clinical study. Second, the number of patients in each group
is unmatched and relatively small, especially in the diuretic
and beta-blocker groups. Therefore, the effect of diuretic
agents or beta-blockers might fail to achieve statistical
significance.
Among randomly recruited hypertensive patients who
received monotherapy, the frequency of use of calcium
antagonists was ;70%, ACE inhibitors 20%, beta-blockers
6% and diuretic agents 4%. This frequency of antihyperten-
sive agents used as monotherapy is consistent with a
Japanese survey that shows that Japanese hypertension
specialists prefer calcium antagonists and ACE inhibitors
(24). In the U.S. (25) and Europe (26), beta-blockers and
diuretic agents are the most widely prescribed antihyperten-
sive drugs for first-line therapy, although recently the use of
calcium antagonists and ACE inhibitors has increased.
Conclusions. We have demonstrated that among the most
frequently prescribed classes of antihypertensive agents, only
ACE inhibitors augment the forearm vascular response to
reactive hyperemia through increases in NO production in
patients with essential hypertension. In addition, a nonin-
vasive method of evaluating reactive hyperemia is a useful
alternative to intra-arterial infusions of vasoactive agents in
the assessment of endothelial function in the forearm
circulation.
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